On 6/16/23 the New England Journal of Medicine released findings of the most recent study in regards to cardiovascular safety and risks of TRT. May be in the interest of some members.
"Patients were randomly assigned to receive daily transdermal 1.62% testosterone gel (dose adjusted to maintain testosterone levels between 350 and 750 ng per deciliter) or placebo gel."